Net Income for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's current net income (TTM) is $1.06B USD. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingNet IncomeSwitch metric
TTM (last 4 quarters)
$1.06B
YoY change
+19.3%
5Y CAGR
+12.7%
Peak year (2025)
$1.06B
Cumulative net income
$7.97B
Net Income history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
Net Income history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Net Income | YoY |
|---|---|---|---|---|
| 2025 | $1.06B | +19.3% | ||
| 2024 | $887.87M | +5.1% | ||
| 2023 | $845.04M | +24.4% | ||
| 2022 | $679.09M | -8.8% | ||
| 2021 | $744.85M | +28.0% | ||
| 2020 | $581.78M | +36.0% | ||
| 2019 | $427.72M | +13.4% | ||
| 2018 | $377.03M | +43.3% | ||
| 2017 | $263.14M | +18.5% | ||
| 2016 | $222.04M | +15.6% | ||
| 2015 | $192.08M | +5.6% | ||
| 2014 | $181.91M | -3.1% | ||
| 2013 | $187.80M | +5.3% | ||
| 2012 | $178.27M | +10.2% | ||
| 2011 | $161.79M | +14.5% | ||
| 2010 | $141.28M | +15.6% | ||
| 2009 | $122.22M | +5.2% | ||
| 2008 | $116.17M | +23.6% | ||
| 2007 | $94.01M | +0.4% | ||
| 2006 | $93.68M | +19.7% | ||
| 2005 | $78.25M | -0.1% | ||
| 2004 | $78.33M | +37.2% | ||
| 2003 | $57.09M | +25.8% | ||
| 2002 | $45.39M | +20.7% | ||
| 2001 | $37.62M | +2.7% | ||
| 2000 | $36.63M | +12.4% | ||
| 1999 | $32.60M | -314.5% | ||
| 1998 | -$15.20M | -28.0% | ||
| 1997 | -$21.10M | -164.7% | ||
| 1996 | $32.60M | +51.6% | ||
| 1995 | $21.50M | +61.7% | ||
| 1994 | $13.30M | +37.1% | ||
| 1993 | $9.70M | +98.0% | ||
| 1992 | $4.90M | +53.1% | ||
| 1991 | $3.20M | — |
Net Income values are taken from IDEXX Laboratories's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual net income for IDEXX Laboratories (IDXX) came in at $1.06B – grew 19.3% year-over-year.
Over 2020–2025 (5 years), IDEXX Laboratories net income expanded at a +12.7% compound annual rate, sustaining 3 straight years of year-over-year growth.
2025 marks the peak net income at $1.06B, with the historical low of -$21.10M recorded in 1997.
IDEXX Laboratories (IDXX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $15.15B.
IDEXX Laboratories Net Income by Year
IDEXX Laboratories Net Income 2025: $1.06B
IDEXX Laboratories net income in 2025 was $1.06B, grew 19.3% from 2024. This figure represents the highest annual value in the available history.
IDEXX Laboratories Net Income 2024: $887.87M
IDEXX Laboratories net income in 2024 was $887.87M, grew 5.1% from 2023.
IDEXX Laboratories Net Income 2023: $845.04M
IDEXX Laboratories net income in 2023 was $845.04M, grew 24.4% from 2022.
IDEXX Laboratories Net Income 2022: $679.09M
IDEXX Laboratories net income in 2022 was $679.09M, declined 8.8% below 2021.
IDEXX Laboratories Net Income 2021: $744.85M
IDEXX Laboratories net income in 2021 was $744.85M.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — Net Income
Companies in the same sector as IDEXX Laboratories, ranked by their latest net income.
| Company | Net Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $102.43B | Healthcare |
| Johnson & Johnson (JNJ) | $26.80B | Healthcare |
| Eli Lilly and Company (LLY) | $20.64B | Healthcare |
| Merck & Co., Inc. (MRK) | $18.25B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $12.06B | Healthcare |
| AstraZeneca PLC (AZN) | $10.26B | Healthcare |
| Amgen Inc. (AMGN) | $7.71B | Healthcare |
| AbbVie Inc. (ABBV) | $4.23B | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's net income?
- Latest reported net income for IDEXX Laboratories (IDXX) is $1.06B (period ending December 31, 2025).
How has IDEXX Laboratories net income changed year-over-year?
- IDEXX Laboratories (IDXX) net income changed +19.3% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories net income?
- IDEXX Laboratories (IDXX) net income compound annual growth rate is +12.7% over the most recent 5 years available.
When did IDEXX Laboratories net income hit its highest annual value?
- IDEXX Laboratories net income reached its highest annual value of $1.06B in 2025.
What was IDEXX Laboratories net income in 2024?
- IDEXX Laboratories (IDXX) net income in 2024 was $887.87M.
What was IDEXX Laboratories net income in 2025?
- IDEXX Laboratories (IDXX) net income in 2025 was $1.06B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.